Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of fenretinide (4-HPR) + rituximab in patients with B-cell lymphoma.

Next Previous
X
Search
Trial Profile

A phase I/II trial of fenretinide (4-HPR) + rituximab in patients with B-cell lymphoma.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fenretinide (Primary) ; Rituximab
  • Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Jan 2013 Planned End Date changed from 1 Jul 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top